Using a battery of tests to evaluate the potential toxicity of remediated and unremediated soils and dusts contaminated with metals. An in vitro model simulating the intact and immature infant intestinal epithelium will be used to determine the changes in solubility and uptake of metals following in situ remediation processes. The earthworm and bacterial luminescence toxicity tests indicate the ecotoxicity of contaminated soils.
Many garden soils, household dusts, and industrial sites are conta ....Using a battery of tests to evaluate the potential toxicity of remediated and unremediated soils and dusts contaminated with metals. An in vitro model simulating the intact and immature infant intestinal epithelium will be used to determine the changes in solubility and uptake of metals following in situ remediation processes. The earthworm and bacterial luminescence toxicity tests indicate the ecotoxicity of contaminated soils.
Many garden soils, household dusts, and industrial sites are contaminated with lead, cadmium, and other metals. These pose a risk to human health, especially of children, and ecosystem health
These tests will be applied to prioritise sites where metal contamination exists and to evaluate the effectiveness of remediation techniques in reducing metal uptake and toxicity.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of ....Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of delivering these by the skin.
This work, in seeking to understand some of the fundamental determinants governing how exogenously applied peptides distribute in the skin, is also contributing to the development of Australian pharmaceutical and cosmetic industries.Read moreRead less
Light-responsive nanomaterials as nanomedicines: new approaches to treating macular degeneration, cancer and other critical unmet therapeutic needs. Nanotechnology is enabling new medicines for the treatment of important diseases such as cancer and macular degeneration. This project will investigate novel nanomaterials for the development of new highly effective medicines that can be controlled after administration, leading to reduced side effects and increased convenience for patients.
Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commerc ....Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commercialisation opportunities in the oral delivery industry and ultimately, should drive the development of efficient oral formulations for biologics. The model should also reduce the need for animal studies.Read moreRead less
Novel click assembled drug-polymer conjugates as next generation drug delivery systems. The purpose of the project is to develop previously inaccessible drug-polymer conjugates with tuneable and sustained drug release rates via a novel polymerisation approach. Ultimately, this will afford next-generation polymer therapeutics suitable for the treatment of a range of disorders and diseases, leading to improvements in heath care.
Pharmacological probes to facilitate preclinical development of modulators of a6 subunit containing nicotinic acetylcholine receptors. Allosteric modulators of alpha7 nicotinic acetylcholine receptors have a promising future as drugs targeting attention deficits in Alzheimer’s disease and schizophrenia but the mechanisms underlying modulation are poorly understood. This project aims to determine its binding site and develop a radioactive labelled compound that competes with its binding. The radi ....Pharmacological probes to facilitate preclinical development of modulators of a6 subunit containing nicotinic acetylcholine receptors. Allosteric modulators of alpha7 nicotinic acetylcholine receptors have a promising future as drugs targeting attention deficits in Alzheimer’s disease and schizophrenia but the mechanisms underlying modulation are poorly understood. This project aims to determine its binding site and develop a radioactive labelled compound that competes with its binding. The radiolabelled compound and a deeper insight into the mode of action will enable development of ligands for positron emission tomography (PET) which will aid in the development of BNC375 as well as other alpha7 modulators.Read moreRead less